Loading...

PerCP anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_PerCP_110907
C57BL/6 thymocytes were stained with CD8 (clone 53-6.7) PerCP and CD4 APC.
  • 53-6dot7_PerCP_110907
    C57BL/6 thymocytes were stained with CD8 (clone 53-6.7) PerCP and CD4 APC.
Compare all formats See PerCP spectral data
Cat # Size Price Quantity Check Availability Save
100731 25 µg $99
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100732 100 µg $270
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP has a maximum absorption of 482 nm and a maximum emission of 675 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Palacios-Arreola M, et al. 2017. Sci Rep. 10.1038/s41598-017-10135-1. PubMed
  2. Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed
  3. Gu J, et al. 2023. J Cell Biochem. 124:557. PubMed
  4. Wang YC, et al. 2023. J Exp Med. 220:. PubMed
  5. Yang Y, et al. 2023. Cancers (Basel). 15:. PubMed
  6. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  7. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  8. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  9. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  10. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  11. Narusawa M, et al. 2014. Cancer Immunol Res. 2:568. PubMed
  12. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  13. Collin R, et al. 2020. J Immunol. 205:133. PubMed
  14. Wang L, et al. 2022. ACS Pharmacol Transl Sci. 5:110. PubMed
  15. Li M, et al. 2022. Cell Death Differ. 29:2034. PubMed
  16. Shen CY, et al. 2022. Pharmaceutics. 14: . PubMed
  17. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  18. Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed
  19. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  20. Fisher E, et al. 2021. Front Immunol. 11:602254. PubMed
  21. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
  22. Khalsa JK, et al. 2020. Nat Commun. 3.175. PubMed
  23. Zhang L, et al. 2020. Front Oncol. 1.243055556. PubMed
  24. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  25. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  26. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  27. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  28. Choudhari R, et al. 2016. Blood. 127: 1297 - 1306. PubMed
  29. Peng X, et al. 2014. J Immunol. 193:1268. PubMed
  30. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  31. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  32. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  33. Yang X, et al. 2019. Oncotarget. 10:4180. PubMed
  34. Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed
  35. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  36. Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed
  37. Shields BD, et al. 2019. Cancer Res. 79:1113. PubMed
  38. Collin R, et al. 2014. J Immunol. 193:3503. PubMed
  39. Ben-Shaanan T, et al. 2016. Nat Med. 10.1038/nm.4133. PubMed
  40. Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed
  41. Levi J, et al. 2020. J Nucl Med. . PubMed
  42. Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed
  43. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  44. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  45. Leisegang M, et al. 2016. Clin Cancer Res. 22: 2734 - 2743. PubMed
  46. Kondratieva T, et al. 2020. PLoS One. 15:e0239668. PubMed
  47. Menotti M, et al. 2019. Nat Med. 25:130. PubMed
  48. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  49. Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed
  50. Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed
  51. Sun Z, Xiao Z 2013. Biochem Biophys Res Commun. 435:472. PubMed
  52. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  53. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  54. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  55. Zhang X, et al. 2019. Nat Commun. 10:4158. PubMed
  56. Sandu I, et al. 2020. Cell Reports. 32(8):108078. PubMed
  57. Wuggenig P, et al. 2020. Commun Biol. 3:130. PubMed
  58. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  59. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  60. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  61. Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed
  62. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
  63. Miyauchi E, et al. 2020. Nature. 585:102. PubMed
  64. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  65. Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed
  66. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  67. Li X, et al. 2016. MBio. 7: 02232-15. PubMed
  68. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
  69. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  70. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  71. Wang J, et al. 2019. Aging (Albany NY). 11:3463. PubMed
  72. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  73. Hickey JW, et al. 2018. Biomaterials. 187:105. PubMed
  74. Hosaka K, et al. 2020. Nat Commun. 3.030555556. PubMed
  75. Byrne K, et al. 2014. J Immunol. 192:1433. PubMed
  76. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  77. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  78. Rinaldi S, et al. 2021. PLoS Pathog. 17:e1009533. PubMed
  79. Jacque E, et al. 2014. J Exp Med. 211:2085. PubMed
  80. Li X, et al. 2022. Cell Death Differ. . PubMed
  81. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  82. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  83. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  84. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  85. Fan X, et al. 2014. PLoS One. 9:107638. PubMed
  86. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  87. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  88. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
AB_893427 (BioLegend Cat. No. 100731)
AB_893427 (BioLegend Cat. No. 100732)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account